Genentech, Xoma Beat Raptiva Warning Suit In 6th Circ.

Law360, New York (September 6, 2012, 7:31 PM EDT) -- The Sixth Circuit on Thursday dismissed a failure-to-warn suit against biotech companies Genentech Inc. and Xoma (U.S.) LLC over psoriasis treatment Raptiva, saying federal law preempts state law fraud-on-the-U.S. Food and Drug Administration claims unless the FDA itself makes a fraud finding.

In a published decision, a three-judge panel ruled that a Michigan federal judge had made the correct decision based on precedent that the companies were entitled to immunity for Raptiva failure-to-warn claims under the Michigan Products Liability Act and that the statute's exceptions to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.